// App-Quantinova.ai

233 : Durability, maintenance and effects of dose reduction following prolonged treatment with baricitinib

Researchers

Presenter

  • Josef S Smolen

Principal Investigators

  • Maxime Dougados

  • Tsutomu Takeuchi

  • Mark C Genovese

  • Boulos Haraoui

  • Rena Klar

  • Arthur Kavanaugh

  • Ricardo B Alonso

  • Jean Dudler

  • Peter C Taylor

  • Peter Nash

  • Cristiano A Zerbini

  • Patrick Durez

  • Georg Pum

  • Subhashini Arthanari

  • Francesco De Leonardis

  • Ronald van Vollenhoven

Medical Centers

  • Rheumatology, Medical University Vienna, Vienna, -

  • Department of Rheumatology, University Paris Descartes and Cochin Hospital, Paris, France

  • The Third Department of Internal Medicine, Kyorin University School of Medicine, Tokyo, Japan

  • Department of Medicine, Stanford University Medical Center, Palo Alto, California, United States

  • Department of Rheumatology, Centre Hospitalier de l'Université de Montréal, Montréal, QC, CANADA

  • Quintiles IMS, Quintiles IMS Holdings, Inc, Durham, NC, uSA

  • Center for Innovative Therapy, Universoty of California San Diego School of Medicine, La Jolla, CA, USA

  • Center for Rheumatology, Hospital Universitario Marqués de Valdecilla, Santander, SPAIN

  • Department of Rheumatology, HFR Fribourg Hopital cantonal, Fribourg, SWITZERLAND

  • Centre for Statistics in Medicine, Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford, Oxford, United Kingdom

  • Department of Medicine, University of Queensland, St Lucia, AUSTRALIA

  • Department of Rheumatology, Centro de Investigação Clinica, Sao Paulo, BRAZIL

  • Rheumatology Department, Cliniques Universitaires Saint-Luc, Brussels, BELGIUM

  • Eli Lilly and Company, Eli Lilly and Company, Geneva, SWITZERLAND

  • Eli Lilly UK, Eli Lilly and Company Ltd, Basingstoke, UNITED KINGDOM

  • Eli Lilly and Company, Eli Lilly and Company, Geneva, SWITZERLAND

  • Division of Clinical Immunology and Rheumatology, VU Univeristy Medical Center, Amsterdam, NETHERLANDS

Locations

  • Austria

  • France

  • Japan

  • United States

  • Canada

  • Spain

  • Switzerland

  • United Kingdom

  • Australia

  • Brazil

  • Belgium

  • Netherlands

Companies

  • N/A

Study Components

Therapeutic Area

  • N/A

Disease

  • N/A

Biomarkers

  • N/A

Drug/Treatment

  • Baricitinib

Outcome

  • N/A

Study Design

  • Randomized

  • Double Blind/Blinded

Phase

  • III

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved